Researcher, Italian National Research (CNR) at Istituto per l’Endocrinologia e l’Oncologia Gaetano Salvatore (IEOS), Naples

Research
1) Characterization of RET gene mutations associated to MEN2 and Hirschsprung syndromes
2) Identification of Ret kinase substrates by a proteomic approach
3) The role of genes that are rearranged with RET in RET/PTC oncogenes

Selected publications
Carlomagno F, Vitagliano D, Guida T, Napolitano M, Vecchio G, Fusco A, Gazit A, Levitzki A, Santoro M. The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Res 2002;62:1077-82.

Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fusco A, Santoro M. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity,
efficiently blocks oncogenic RET kinases. Cancer Res 2002;62:7284-90.

Carlomagno F, Vitagliano D, Guida T, Basolo F, Castellone MD, Melillo RM, Fusco A, Santoro M.
Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). J Clin Endocrinol Metab 2003;88:1897-902.

Carlomagno F, Guida T, Anaganti S, Vecchio G, Fusco A, Ryan AJ, Billaud M, Santoro M.
Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 2004;23:6056-63.

Santoro M, Melillo RM, Carlomagno F, Vecchio G, Fusco A. RET: normal and abnormal functions.
Endocrinology 2004 Aug 26 [Epub ahead of print].